222530-33-8Relevant articles and documents
Polycyclic amide derivative as CDK9 inhibitor, and preparation method and application thereof
-
, (2021/07/24)
The invention belongs to the technical field of polycyclic amide derivatives, and particularly relates to a polycyclic amide derivative as a CDK9 inhibitor, and a preparation method and application thereof. The polycyclic amide derivative shows excellent CDK9 enzyme inhibitory activity, and can be used for preparing drugs for treating cancers, especially hematologic cancers including acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, follicular lymphoma and the like and solid tumors, such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia and follicular lymphoma, including breast cancer, prostate cancer, ovarian cancer, hepatocellular carcinoma, pancreatic cancer, kidney cancer, stomach cancer, colorectal cancer, lung cancer and the like.
Discovery of LY3325656: A GPR142 agonist suitable for clinical testing in human
Chen, Jiehao,Efanov, Alexander M.,Fang, Xiankang,Jiang, Yi,Jun Zhang, Xue,Li, Lei,Lin, Hua V.,Liu, Jia,Liu, Lian Zhu,Long Hu, Zhi,Ma, Tianwei,Thomas, Melissa K,Wang, Fan,Wang, Jingru,Xiao, Fei,Xu, Jianfeng,Zeng, Mi,Zhang, Lei,Zhen Zhang, Hai,Zhou, Jingye,Zou, Haixia,Zou, Zack
supporting information, (2020/01/28)
The discovery and optimization of a novel series of GPR142 agonists are described. These led to the identification of compound 21 (LY3325656), which demonstrated anti-diabetic benefits in pre-clinical studies and ADME/PK properties suitable for human dosing. Compound 21 is the first GPR142 agonist molecule advancing to phase 1 clinic trials for the treatment of Type 2 diabetes.
PYRROLOPYRIMIDINES FOR USE IN INFLUENZA VIRUS INFECTION
-
Paragraph 0101-0102, (2017/09/20)
The invention relates to compounds having the structure of formula (I) which can be used for the treatment of or against influenza infections.